Application number	Application type	Number of applications	Performance	Target days
1	Complex timetable (National new MA applications) Complex new MA applications, e.g. novel therapies, new actives	20	100%	210.0
2	Major timetable (National) New MRLs. All other MA applications (excl. MAPI and Copycats)	3	100%	180.0
3	Standard timetable (National Type II variations. New MA - MAPIs and Copycats. New VHRs)	53	100%	120.0
4	Shortened timetable (Type IB variations. New ATC (type B). Out of Scope MRLs)	115	74.8%	60.0
5	Minor timetable (National) Type IA variations. Administrative Type IB variations. New ATC (Type A/S). ATC variations and renewals.	498	83.3%	30.0
6	Parallel Assessment with EU Procedures	263	98.5%	-
7	Shared Assessment with International Partners	0	-	-
8	Batch timetable (National) specific Batch Control	46	100%	20.0
9	Autogenous Vaccines. New & Variations	3	100%	45.0

# Published Standard Number 1 – Applications (National)

# Published Standard Number 1 – Applications (Other)

Application number	Application Type	Number of applications	Performance
10	Mock-up period completed within 20 days (or up to 40 days for parallel applications involving different QRD sources)	325	93.2%
11	Validation	656	37.5%
12	Issue of authorised documentation	1470	20.0%

# Published Standard Number 1 – Applications (European - NI)

Application number	Application Type	Number of applications	Performance
13	New Decentralised (DCP)	5	100%
14	New Mutual Recognition (MRP)	7	100%
15	MRP Variations (Type IB & II)	146	100%

Application number	Application type	Total number	Performance
16	Publishing Summary of Product Characteristics (SPCs)	54	100%
17	Publishing Public Assessment Reports (PuARs)	13	100%
18	Updating PuARs	4	100%

### Published Standard Number 2 – Public Assessment Reports

## Published Standard Number 3 – Quality of Documentation

Applicatio	n number	Application type	Number of applications	Performance
19	Unreturn	ed Documents	2345	98%

#### Published Standard Number 4 – Product Defects

Task number	Task	Number of tasks	Performance
20	Product Defects reports	23	100%
	High risk <5 days	1	-
	Low risk <10 days	22	-

#### Published Standard Number 5 – Import, Export and Batch Release Schemes

Application number	Application Type	No of Apps	Performance	Target Days
21	Applications for new products	88	97.7%	15/25
22	Applications for previously imported products	144	99%	15
23	All other urgent applications	90	98.8%	-
	Urgent	1		2
	Non Urgent	89		10
24	Instant Import Certificates	13,807	-	-
25	Export	88	100%	10
26	Batch Release	864	99.8%	10

## Published Standard Number 6 – Pharmacovigilance

Task number	Task	No.	Performance
27	Human, Animal & Environmental AERs	1579	100%
28	PSURs	593	100%
29	Inspections	7	100%

Task number	Task	No.	Performance	Target Days
30	Inspections within 3 years (GMP)	9	100%	-
	Within 5 years (GDP) of last inspection	14	Joint with above	-
31	Inspection Deficiency Reports	16	100%	30.0
32	(GMP) Certificates or (GDP) final reports sent	16	100%	90.0
33	Approval of new Feed business operators and SQP retailer sites	20	100%	45.0
34	Final inspection report to Feed business operators and SQP retailers	131	100%	30.0

### Published Standard Number 7– Inspections

## Published Standard Number 8 – Enforcement

Task number	Task	No.	Performance
35	Quarterly VMR Breaches	1	100%
36	Intelligence Activity	13	100%

### Published Standard Number 9 – Residues

Task number	Task	No.	Performance
37	Quarterly Non-Compliance Data	1	100%
38	Sample Testing	10,521	100%

#### **Additional information**

The VMD continuously monitors all targets and puts in place countermeasures, where possible, to ensure targets are met.